logo
Plus   Neg
Share
Email

Fannie Mae Names Hugh Frater Interim CEO

Fannie Mae (FNMA.OB), Monday said it has appointed Hugh Frater as Interim Chief Executive Officer, effective October 16, 2018.

Frater will succeed Timothy Mayopoulos, who announced his intention to depart in July 2018 and will leave the company on October 15, 2018.

"On behalf of the Board of Directors, we are excited to have an executive with such broad experience and impressive track record as our new Interim CEO," said Egbert Perry, Chairman of Fannie Mae's Board of Directors. "Hugh has a deep understanding of the housing and the financial services industries, and his experience on our Board makes him an ideal choice to lead Fannie Mae as the Interim CEO."

"I have great respect for Fannie Mae and the significant role it plays in our housing system," said Hugh Frater, incoming Interim CEO. "I am humbled and excited to serve at an institution that has made tremendous strides in supporting its customers and making housing more affordable for millions of Americans while reducing risk to taxpayers."

Frater has served on Fannie Mae's Board since 2016. He has held a number of executive and management roles throughout his career. Frater currently serves as Non-Executive Chairman of the Board of VEREIT, Inc. and as a director of ABR Reinsurance Capital Holdings Ltd.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
Follow RTT